Literature DB >> 19491686

The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden.

Anna Ringborg1, Donald D Yin, Mats Martinell, Jan Stålhammar, Peter Lindgren.   

Abstract

BACKGROUND: Estimates of the economic impact of cardiovascular events in patients with type 2 diabetes are scarce. The aim of this study was to determine the health care costs associated with acute myocardial infarction (AMI) and stroke in patients with type 2 diabetes in Sweden.
DESIGN: Population-based open cohort study of 9941 patients with type 2 diabetes retrospectively identified in primary care records at 26 centres in Uppsala County.
METHODS: Episodes of AMI and stroke suffered by study patients were tracked in the Swedish National Inpatient Register. Annual per patient costs of health care were computed for the years 2000-2004 using register data covering inpatient care, outpatient hospital care, primary care and drugs. Panel data regression was applied to determine the impact of suffering a first or repeat AMI or stroke on health care costs during the year of the event and in subsequent years.
RESULTS: Total health care costs of patients suffering a first AMI/stroke increased by 4.1/6.5 during the year of the event [95% confidence interval (CI): 3.1-5.4/4.9-8.5] and by 1.1/1.4 during subsequent years (95% CI: 1.0-1.3/1.2-1.6), controlling for age, sex, the event of amputation and presence of renal failure, heart failure and diabetic eye disease. Total health care costs of patients suffering a first or repeat AMI/stroke increased by 4.1/6.4 during the year of an event (95% CI: 3.2-5.2/5.0-8.1) but were not significantly higher during subsequent years.
CONCLUSION: Estimates of the costs related to major cardiovascular complications of type 2 diabetes are critical input to economic evaluations.

Entities:  

Mesh:

Year:  2009        PMID: 19491686     DOI: 10.1097/HJR.0b013e32832d193b

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  7 in total

1.  The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan.

Authors:  Haruhisa Fukuda; Shunya Ikeda; Takeru Shiroiwa; Takashi Fukuda
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

2.  Predictors of early and late stroke following cardiac surgery.

Authors:  Richard Whitlock; Jeff S Healey; Stuart J Connolly; Julie Wang; Matthew R Danter; Jack V Tu; Richard Novick; Stephen Fremes; Kevin Teoh; Vikas Khera; Salim Yusuf
Journal:  CMAJ       Date:  2014-07-21       Impact factor: 8.262

3.  Cost of cardiovascular diseases and renal complications in people with type 2 diabetes mellitus in the Kingdom of Saudi Arabia: A retrospective analysis of claims database.

Authors:  Ahmed Hamden Al-Jedai; Hajer Yousef Almudaiheem; Dema Abdulrahman Alissa; Hadi Saeed Al-Enazy; Ghazwa B Korayem; Ahlam Alghamdi; Shabab Alghamdi
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

4.  Automated data extraction--a feasible way to construct patient registers of primary care utilization.

Authors:  Mats Martinell; Jan Stålhammar; Johan Hallqvist
Journal:  Ups J Med Sci       Date:  2012-03       Impact factor: 2.384

Review 5.  Patient-level costs of major cardiovascular conditions: a review of the international literature.

Authors:  Gina Nicholson; Shravanthi R Gandra; Ronald J Halbert; Akshara Richhariya; Robert J Nordyke
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-21

6.  Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden.

Authors:  Giovanni Ferrara; Lisen Arnheim-Dahlström; Karen Bartley; Christer Janson; Klaus-Uwe Kirchgässler; Aaron Levine; C Magnus Sköld
Journal:  Pulm Ther       Date:  2019-03-05

7.  Direct Medical Costs of Incident Complications in Patients Newly Diagnosed With Type 2 Diabetes in China.

Authors:  Xiaoning He; Yawen Zhang; Yan Zhou; Chaohui Dong; Jing Wu
Journal:  Diabetes Ther       Date:  2020-11-18       Impact factor: 2.945

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.